Alibaba Listing a Shot of Confidence for H.K.: BDA China
Law360, Hong Kong (June 1, 2015, 11:30 AM EDT) -- Chinese biotechnology company 3SBio, which was taken private by its CEO and a private equity firm in 2013, said Monday that it will seek up to HK$5.51 billion ($710.45 million) through an initial public offering on the Hong Kong Stock Exchange to expand its pharmaceutical product offerings through acquisitions.
The offering will include 606.1 million shares that are expected to be priced at HK$8.30 to HK$9.10 per share, putting the total potential of the IPO at up to HK$5.51 billion, according to a prospectus 3SBio filed with the Hong Kong bourse on Monday.
The share sale will include 484.9 million new shares from...
Stay ahead of the curve
In the legal profession, information is the key to success.
You have to know what’s happening with clients, competitors, practice areas, and industries.
Law360 provides the intelligence you need to remain an expert and beat the competition.
- Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
- Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
- Create custom alerts for specific article and case topics and so much more!
TRY LAW360 FREE FOR SEVEN DAYS